News | June 11, 2007

Medtronic Presents 12-Month Results from VALOR Clinical Study

June 12, 2007 — Dr. Ronald M. Fairman, principal investigator for the VALOR clinical study evaluating the Talent Thoracic Stent Graft System, today presented positive 12-month results at a late-breaking session during the annual meeting of the Society for Vascular Surgery in Baltimore.

Sponsored by Medtronic, VALOR is a prospective, multi-center study of 195 test group patients with thoracic aortic aneurysms who were considered candidates for open surgical repair. The primary endpoint is "all cause" mortality at 12 months, comparing minimally invasive endovascular stent graft treatment to a historical surgical control group.

Dr. Fairman reported that patients in the test group who received the Talent Thoracic Stent Graft had a statistically significant reduction in all-cause mortality 16.1% compared to the surgical control rate of 29.8% (p= less than0.001) - using literature-derived figures for the open surgery group. Aneurysm-related mortality in the VALOR trial was 3.1% at 12 months. The Talent Thoracic system also had a successful aneurysm treatment rate of 89.2%. This was defined as no aneurysm growth greater than 5 mm between 1 and 12 months and the absence of a Type I endoleak.

In addition, the Talent Thoracic Stent Graft system demonstrated 100% patency, which is a measure of the graft's ability to resist collapse and remain open for proper blood flow, and there was a 99.5% success rate in deploying the stent graft. Also, the stent graft system used in the study was available in diameters ranging from 22 mm to 46 mm. Without this wide range of sizes, approximately 25% of the test arm patients in the VALOR trial would not have had the minimally-invasive stent graft therapy available to them as a treatment alternative.

Based on the VALOR data, Medtronic submitted its pre-market approval application to the U.S. Food and Drug Administration in March 2007. The device is awaiting approval. The Talent Thoracic system has been available outside the United States since 1998, with more than 20,000 implants.

For more information:

Related Content

Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.
FDA Concerned About Increase in stent graft Endovascular Type III Leaks
News | Stent Grafts | October 09, 2017
October 9, 2017 — The U.S.
Gore Announces First-in-Human Use of Gore TAG Conformable Thoracic Stent Graft
News | Stent Grafts | July 17, 2017
W. L. Gore & Associates Inc. announced the first patient implant of the Gore TAG Conformable Thoracic Stent Graft...
News | Stent Grafts | April 06, 2017
Endologix Inc. announced that the first patients were treated in the Expanding Patient Applicability with Polymer...
Gore, Viabahn VBX Balloon Expandable Endoprosthesis, stent graft, iliac artery, FDA approval
Technology | Stent Grafts | January 31, 2017
W. L. Gore & Associates (Gore) announced that the Gore Viabahn VBX Balloon Expandable Endoprosthesis (VBX Stent...
Lombard Medical, Aorfix endovascular stent graft, Japanese regulatory approval, IntellFlex LP Delivery System
News | Stent Grafts | January 11, 2017
January 11, 2017 — Lombard Medical Inc.
stent grafts, fluid flow model, clotting risk, Journal of Vascular Surgery

An anterior view is shown of the geometries of each of the graft configurations: (A) fenestrated, (B) antegrade branched, (C) retrograde branched, and (D) manifold stent graft. Image courtesy of Taylor Suess, et al.

News | Stent Grafts | January 05, 2017
January 5, 2017 — Whether patients with mechanical heart valves and stents must take blood thinners depends on how ef
News | Stent Grafts | December 13, 2016
Lombard Medical Inc. announced that its Altura endovascular stent graft system was featured in a scientific...
Overlay Init